| Document and Entity Information | 9 Months Ended | |
| Sep. 30, 2013 | Dec. 10, 2014 | |
| Document And Entity Information | ' | ' |
| Entity Registrant Name | 'NMI Health, Inc. | ' |
| Entity Central Index Key | '0001088213 | ' |
| Document Type | '10-Q | ' |
| Document Period End Date | 30-Sep-13 | ' |
| Amendment Flag | 'false | ' |
| Current Fiscal Year End Date | '--12-31 | ' |
| Is Entity a Well-known Seasoned Issuer? | 'No | ' |
| Is Entity a Voluntary Filer? | 'No | ' |
| Is Entity's Reporting Status Current? | 'No | ' |
| Entity Filer Category | 'Smaller Reporting Company | ' |
| Entity Common Stock, Shares Outstanding | ' | 20,007,170 |
| Document Fiscal Period Focus | 'Q3 | ' |
| Document Fiscal Year Focus | '2013 | ' |
| Balance Sheets (Unaudited) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
| CURRENT ASSETS | ' | ' |
| Cash | $0 | $9,409 |
| Accounts receivable | 28,900 | 0 |
| Other receivable | 7,553 | 0 |
| Prepaid expenses | 30,000 | 0 |
| Inventory, net | 41,554 | 42,165 |
| Total current assets | 108,007 | 51,574 |
| FIXED ASSETS | ' | ' |
| Equipment and molds | 933 | 973 |
| Accumulated depreciation | -40 | -519 |
| Net fixed assets | 893 | 454 |
| OTHER ASSETS | ' | ' |
| Non-performing assets | 4,230 | 4,230 |
| Total assets | 113,130 | 56,258 |
| Current Liabilities | ' | ' |
| Customer advances | 21,047 | 12,545 |
| Accounts payable | 205,300 | 449,331 |
| Acounts payable - related party | 0 | 10,380 |
| Advances from related party | 423,249 | 207,200 |
| Accrued expenses | 686,799 | 687,336 |
| Notes payable | 696,226 | 521,157 |
| Note payable - related party | 30,000 | 25,000 |
| Total current liabilities | 2,062,621 | 1,912,949 |
| Total liabilities | 2,062,621 | 1,912,949 |
| STOCKHOLDERS' DEFICIT | ' | ' |
| Common stock, $.001 par value, 100,000,000 shares authorized; 10,465,619 and 9,869,710 shares outstanding, respectively | 10,466 | 98,695 |
| Additional paid-in capital | 21,874,495 | 21,624,265 |
| Accumulated deficit | -23,834,452 | -23,579,651 |
| Total stockholders' deficit | -1,949,491 | -1,856,691 |
| Total liabilities and stockholders' deficit | $113,130 | $56,258 |
| Balance Sheets (Parenthetical) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
| STOCKHOLDERS' DEFICIT | ' | ' |
| Common stock, par value | $0.00 | $0.00 |
| Common stock, authorized shares | 100,000,000 | 100,000,000 |
| Common stock, outstanding shares | 10,465,619 | 9,869,710 |
| Statements of Operations (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
| Income Statement [Abstract] | ' | ' | ' | ' |
| NET SALES | $59,772 | $154,775 | $232,291 | $454,513 |
| COSTS AND EXPENSES | ' | ' | ' | ' |
| Cost of goods sold | 18,582 | 122,970 | 158,023 | 326,346 |
| Research and development | 16,268 | 0 | 16,268 | 115 |
| Selling, general and administrative | 90,918 | 174,158 | 538,361 | 541,988 |
| Total expenses | 125,768 | 297,128 | 712,652 | 868,449 |
| LOSS FROM OPERATIONS | -65,996 | -142,353 | -480,361 | -413,936 |
| OTHER INCOME (EXPENSE) | ' | ' | ' | ' |
| Gain on settlement of vendor liabilities and other | 97,957 | 125 | 270,181 | 7,490 |
| Loss on settlement of debt | -10,604 | 0 | -10,604 | 0 |
| Interest expense | -11,969 | -10,773 | -34,017 | -31,977 |
| Total other income (expense) | 75,384 | -10,648 | 225,560 | -24,487 |
| NET INCOME (LOSS) | $9,388 | ($153,001) | ($254,801) | ($438,423) |
| BASIC AND FULLY-DILUTED INCOME (LOSS) PER SHARE | $0 | ($0.02) | ($0.03) | ($0.05) |
| WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING | 10,415,337 | 8,841,768 | 10,053,584 | 8,638,740 |
| Statements of Cash Flows (Unaudited) (USD $) | 9 Months Ended | |
| Sep. 30, 2013 | Sep. 30, 2012 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ' | ' |
| Net loss | ($254,801) | ($438,423) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' |
| Depreciation | 152 | 498 |
| Provision for inventory obsolescence | 0 | 7,609 |
| Loss on disposition of equipment | 341 | 0 |
| Common stock issued for services | 123,000 | 161,650 |
| Loss on settlement of debt | 10,604 | 0 |
| Gain on settlement of vendor liabilities | -243,207 | -7,490 |
| Changes in operating assets and liabilities: | ' | ' |
| Accounts receivable | -28,900 | 422 |
| Other receivable | -7,553 | 0 |
| Prepaid expenses and other | -30,000 | 14,543 |
| Inventory | 611 | -14,448 |
| Customer advances | 8,502 | -137,972 |
| Accounts payable | -10,324 | 29,194 |
| Accrued expenses | 193,479 | 224,195 |
| Net cash used in operating activities | -238,096 | -160,222 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ' | ' |
| Purchase of equipment | -933 | 0 |
| Net cash used in investing activities | -933 | 0 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ' | ' |
| Proceeds from issuance of common shares | 0 | 25,000 |
| Proceeds from advances of related parties | 210,000 | 104,460 |
| Repayment of advances from related party | -10,380 | -24,730 |
| Proceeds from issuance of short-term note payable | 30,000 | 5,149 |
| Repayments of short-term note payable | 0 | -1,692 |
| Net cash provided by financing activities | 229,620 | 108,187 |
| NET INCREASE (DECREASE) IN CASH | -9,409 | -52,035 |
| CASH AT BEGINNNING OF PERIOD | 9,409 | 61,504 |
| CASH AT END OF PERIOD | 0 | 9,469 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ' | ' |
| Cash paid for interest | 0 | 0 |
| Cash paid for income taxes | 0 | 0 |
| NON-CASH INVESTING AND FINANCING ACTIVITIES | ' | ' |
| Reduction of note payable due to a reduction in prepaid insurance | 0 | 3,457 |
| Common stock issued for settlement of notes payable and accrued expenses | $28,396 | $8,703 |
| 1. Basis of Presentation | 9 Months Ended |
| Sep. 30, 2013 | |
| Accounting Policies [Abstract] | ' |
| 1. Basis of Presentation | ' |
| The financial information included herein is unaudited and has been prepared consistent with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8, Rule 8.03 of Regulation S-K. Accordingly, these financial statements do not include all information required by generally accepted accounting principles for annual financial statements. These statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's annual report on Form 10-Kfor the year ended December 31, 2012, from which the balance sheet information as of that date is derived. These interim financial statements contain all adjustments necessary in the opinion of management for a fair statement of results for the interim periods presented. | |
| The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year. | |
| Certain minor reclassifications in prior period amounts have been made to conform to the current period presentation. |
| 2. Going Concern | 9 Months Ended |
| Sep. 30, 2013 | |
| Text Block [Abstract] | ' |
| 2. Going Concern | ' |
| The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, in addition to a working capital deficiency at September 30, 2013, the Company has incurred negative cash flow from operations and losses which have substantially increased its operating deficit at September 30, 2013. These factors raise substantial doubt about the Company’s ability to continue as a going concern. | |
| The Company’s ability to continue as a going concern will be dependent upon economic developments and the success of management's plans as set forth below, which cannot be assured. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. Management and board members are continuing to discuss other alternative financing options, but no definitive proposals or agreements have been reached. | |
| The foregoing notwithstanding, management does not believe the Company currently has sufficient capital to sustain its planned business activities for the next twelve months following the issuance of these financial statements. Accordingly, while management has historically been successful generating sufficient funds to sustain operations, there is no assurance that they will continue to do so. Nevertheless, the Company may seek additional capital to sustain its operations, either through equity or loans, possibly unsecured, until such time as its operations are self-sustaining. These funds will be required to continue the Company’s efforts to generate sales of its products and to provide sufficient working capital to meet the expected sales demand. |
| 3. Significant Transactions | 9 Months Ended |
| Sep. 30, 2013 | |
| Supplemental Cash Flow Elements [Abstract] | ' |
| 3. Significant Transactions | ' |
| In April 2013 the Company authorized a name change from Nano Mask, Inc. to NMI Health, Inc. to better reflect the nature of its products. On June 5, 2013 the Company completed a 1 for 10 reverse split of its common shares. Following the reverse split, the Company maintained 9,869,710 common shares outstanding. | |
| In July, 2013 the Company issued 465,909 common shares to a key officer for his $123,000 in accrued payroll. | |
| As of August 1, 2013, a Company affiliate converted a note of $25,000, plus interest of $3,396, into 130,000 common shares. The shares were issued at a fair value of $39,000 resulting in a loss on settlement of debt of $10,604. On September 22, 2013 the same shareholder loaned the Company $30,000, plus interest, at an annual rate of 10%, convertible at $0.05 per share. The note is unsecured and is due on September 22, 2015. | |
| Repayments of advances from a related party were made in the amount of $10,380 for the nine months ended September 30, 2013. | |
| In August, 2013 a judgment was awarded to Applied Nanoscience, Inc. against the Company in the amount of $601,041, including interest at prime rate, plus 2%, and attorney fees. The Company had already reflected a balance owed in excess of this. In September 2013, a note payable for $13,832, plus related interest, expired under applicable statutes of limitation. These two events both generated gains of $97,957 for the Company. | |
| During the nine months ended September 30, 2013, the Company received cash advances of $210,000 from one executive officer with no specific repayment terms and another officer paid expenses on behalf of the Company in the amount of $6,049. The total balance outstanding at September 30, 2013 is $423,249. | |
| A gain of $145,251 was generated from expiry of certain accounts payable under applicable statutes of limitations during the nine months ended September 30, 2013. Also, during the nine months ended September 30, 2013 the Company realized a gain of $26,973 from disposition of common shares in Medmarc Insurance Company which was a mutual insurance company that was bought by another company. Since the Company had maintained its insurance through Medmarc, the Company was designated a percentage of the final sales proceeds from the sale of Medmarc. $7,553 was withheld as Federal income taxes and is reflected as other receivable. | |
| 4. Subsequent Events | 9 Months Ended |
| Sep. 30, 2013 | |
| Subsequent Events [Abstract] | ' |
| 4. Subsequent Events | ' |
| Subsequent to September 30, 2013, the Company received cash advances from one executive officer of $27,200 and another officer incurred expenses of $1,658 on behalf of the Company. | |
| On April 15, 2014 a note for $30,000 including interest of $1,696 was converted into 633,921 common shares. Further, on May 15, 2014 the same shareholder provided $20,000 at no interest as an unsecured loan. | |
| Also on April 15, 2014, Applied Nanoscience, Inc. and the Company agreed to settle the outstanding $601,041 judgment for 500,000 restricted common shares (valued at $0.025 per share on the date of the settlement) and $175,000 payable in three instalments ending on October 15, 2014. The Company has paid $20,000 to date. | |
| Finally, on April 15, 2014 the Company authorized the issuance of 4,610,810 common shares to Company officers and employees at a value of $0.15 per share in satisfaction of accrued payroll and director fees. And on the same date, 500,000 common shares valued at $12,500 were awarded to two individuals for services performed. | |
| During the two months ended June 30, 2014, 75,000 shares of common stock were issued in a private placement to two individual investors for $15,000 in cash. Also, in November 2014, an additional 125,000 common shares were issued in a private placement to an individual for $25,000 in cash. | |
| On October 9, 2014 the Company issued 2,222,000 common shares to an affiliate shareholder in settlement of his unsecured loan of $444,400. Also, on the same date officers and employees agreed to receive 874,820 common shares to settle $131,223 in accrued payroll. | |
| Subsequent to September 30, 2013 the Company generated $25,025 in gains from expiry of certain accounts payable under applicable statutes of limitations. Also, the Company generated gains of $487,137 from settlement of various notes payable and from the expiry of certain notes under applicable statutes of limitations. |
| 5. Contingencies | 9 Months Ended |
| Sep. 30, 2013 | |
| Commitments and Contingencies Disclosure [Abstract] | ' |
| 5. Contingencies | ' |
| On March 5 2012, the Company received a complaint from a certain attorney seeking collection of his invoices in the amount of $167,167, plus interest and litigation expenses. The Company does not believe the claim has any merit and has submitted a motion for dismissal. At this point, the Company has been awaiting the claimant’s amendment to his claim. Recently, the Company decided to pursue further efforts to seek dismissal of the complaint. | |
| On or about May 8, 2012, the Company received a complaint from a certain former employee seeking collection of his charges as a distributor and as an employee in the amount of $409,525, plus interest and litigation expenses. The Company believes the likelihood of loss in this case is remote and intends to offset for certain expenditures made by the Company caused by employee. The Company has already recognized $37,500 as a liability at September 30, 2013. | |
| 3. Significant Transactions (Details Narrative) (USD $) | 9 Months Ended | |
| Sep. 30, 2013 | Sep. 30, 2012 | |
| Significant Transactions Details Narrative | ' | ' |
| Repayments of advances from related party | $10,380 | $24,730 |
| Gain genereated by writing off payables | $145,251 | ' |
| 4. Subsequent Events (Details Narrative) (USD $) | Sep. 30, 2013 |
| Subsequent Events [Abstract] | ' |
| Cash advances from executive officers | $27,200 |
